文献速递淋巴瘤

纳武利尤单抗治疗复发/难治性经典型霍奇金淋巴瘤:关键II期CheckMate 205研究的5年生存结果

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
PubMed 文献 · Blood Adv · 2023-01-01

CheckMate 205 II期研究5年随访更新显示,自体造血干细胞移植(auto-HCT)失败的复发/难治性经典型霍奇金淋巴瘤患者接受纳武利尤单抗3 mg/kg每2周静脉给药,客观缓解率71.2%(95%CI 65.1-76.8),完全缓解率21.4%(95%CI 16.4-27.1),5年总生存率71.4%(95%CI 64.8-77.1),未发现新的或非预期安全性信号。

要点

  • auto-HCT失败的R/R cHL患者中,纳武利尤单抗客观缓解率71.2%,完全缓解率21.4%。
  • 中位无进展生存期15.1个月,中位总生存期未达到,5年总生存率71.4%。
  • C队列中持续完全缓解1年可停药、复发再治疗,3例停药后再治疗均获客观缓解。

核心结论

  • CheckMate 205的5年随访显示,auto-HCT失败的复发/难治性经典型霍奇金淋巴瘤患者接受纳武利尤单抗治疗的总生存良好,疗效和安全性得到确认。
  • 结果提示患者可在持续完全缓解后停药,并在疾病进展时重新开始治疗。

研究设计与样本

  • II期CheckMate 205研究,纳入243例auto-HCT失败的复发/难治性经典型霍奇金淋巴瘤患者,分为A队列(n=63,未接受过维布妥昔单抗)、B队列(n=80,auto-HCT后接受维布妥昔单抗)和C队列(n=100,auto-HCT前后接受维布妥昔单抗)。
  • 纳武利尤单抗3 mg/kg静脉给药,每2周一次,直至疾病进展或出现不可接受的毒性;C队列中完全缓解持续1年的患者可停药,复发时重新开始治疗。
  • 中位随访约5年。

主要发现

  • 243例患者客观缓解率为71.2%(95%CI 65.1-76.8),完全缓解率为21.4%(95%CI 16.4-27.1)。
  • 中位缓解持续时间18.2个月(95%CI 14.7-26.1),中位完全缓解持续时间30.3个月,中位部分缓解持续时间13.5个月。
  • 中位无进展生存期15.1个月(95%CI 11.3-18.5);中位总生存期未达到,5年总生存率71.4%(95%CI 64.8-77.1)。
  • C队列中3例在完全缓解时停药并随后重新治疗的患者均获得客观缓解。
  • 未发现新的或非预期的安全性信号。

临床怎么用

  • 作者认为,auto-HCT失败的复发/难治性经典型霍奇金淋巴瘤患者接受纳武利尤单抗治疗可获得良好的总生存。
  • 作者提出,患者可在持续完全缓解后停药,并在疾病进展时重新开始治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) for whom autologous hematopoietic cell transplantation (auto-HCT) had failed experienced frequent and durable responses to nivolumab in the phase 2 CheckMate 205 trial. We present updated results (median follow-up, ∼5 years). Patients with R/R cHL who were brentuximab vedotin (BV)-naive (cohort A), received BV after auto-HCT (cohort B), or received BV before and/or after auto-HCT (cohort C) were administered with nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity. Patients in cohort C with complete remission (CR) for 1 year could discontinue nivolumab and resume upon relapse. Among 243 patients (cohort A, n = 63; B, n = 80; and C, n = 100), the objective response rate (ORR) was 71.2% (95% confidence interval [CI], 65.1-76.8); the CR rate was 21.4% (95% CI, 16.4-27.1). Median duration of response, CR, and partial remission were 18.2 (95% CI, 14.7-26.1), 30.3, and 13.5 months, respectively. Median progression-free survival was 15.1 months (95% CI, 11.3-18.5). Median overall survival (OS) was not reached; OS at 5 years was 71.4% (95% CI, 64.8-77.1). In cohort C, all 3 patients who discontinued in CR and were subsequently re-treated achieved objective response. No new or unexpected safety signals were identified. This 5-year follow-up of CheckMate 205 demonstrated favorable OS and confirmed efficacy and safety of nivolumab in R/R cHL after auto-HCT failure. Results suggest patients may discontinue treatment after persistent CR and reinitiate upon progression. This trial was registered at www.clinicaltrials.gov as #NCT02181713.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023. PMID: 37530622. doi:10.1182/bloodadvances.2023010334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。